Yihe Daida to Liver Cirrhosis
This is a "connection" page, showing publications Yihe Daida has written about Liver Cirrhosis.
Connection Strength
1.205
-
Impact of Disease-Specific Treatment and Non-Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC. Liver Int. 2026 05; 46(5):e70628.
Score: 0.240
-
Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study. BMJ Open Gastroenterol. 2026 Mar 27; 13(1).
Score: 0.239
-
Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis?C and Cirrhosis. Adv Ther. 2024 Feb; 41(2):744-758.
Score: 0.204
-
Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis. J Gastrointest Cancer. 2020 Jun; 51(2):461-468.
Score: 0.159
-
Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. Infect Dis Clin North Am. 2018 06; 32(2):253-268.
Score: 0.139
-
Changing trends in complications of chronic hepatitis C. Liver Int. 2018 02; 38(2):239-247.
Score: 0.131
-
Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat. 2023 09; 30(9):746-755.
Score: 0.049
-
The Persistence of Underreporting of Hepatitis C as an Underlying or Contributing Cause of Death, 2011-2017. Clin Infect Dis. 2021 09 07; 73(5):891-894.
Score: 0.043